News coverage about Infinity Pharmaceuticals (NASDAQ:INFI) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Infinity Pharmaceuticals earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 47.9179793503958 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the headlines that may have effected Accern Sentiment’s rankings:
- Hot Stock in Focus – Infinity Pharmaceuticals Inc (NASDAQ: INFI) – Stocks Market Cap (stocksmarketcap.com)
- Infinity Pharmaceuticals, Inc. (INFI) stock price increased 15.42% from its 20-SMA – The Stocks News (press release) (thestocksnews.com)
- How much this stock is Risky? Infinity Pharmaceuticals, Inc. (INFI)’s … – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Technical Indicators should not be overlooked on Infinity Pharmaceuticals, Inc. (INFI) – Wall Street Morning (wallstreetmorning.com)
- Infinity Pharmaceuticals, Inc. (INFI) crosses above SMA-50 with 23.21% – The Stocks News (press release) (thestocksnews.com)
Infinity Pharmaceuticals (NASDAQ INFI) opened at $2.56 on Tuesday. The stock has a market capitalization of $134.58, a price-to-earnings ratio of -3.08 and a beta of 2.74. Infinity Pharmaceuticals has a one year low of $0.93 and a one year high of $3.75.
Infinity Pharmaceuticals (NASDAQ:INFI) last issued its quarterly earnings results on Thursday, March 15th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.11. sell-side analysts predict that Infinity Pharmaceuticals will post -1.07 EPS for the current year.
Separately, ValuEngine lowered Infinity Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st.
TRADEMARK VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Infinity Pharmaceuticals (INFI) Share Price” was posted by Stock Observer and is the property of of Stock Observer. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.thestockobserver.com/2018/03/20/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-infinity-pharmaceuticals-infi-share-price.html.
Infinity Pharmaceuticals Company Profile
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.